Virtual Library
Start Your Search
Kenya Kanazawa
Author of
-
+
P3.01 - Advanced NSCLC (Not CME Accredited Session) (ID 967)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 2
- Moderators:
- Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall
-
+
P3.01-111 - Efficacy and Safety of Cytotoxic Drug Chemotherapy After First-Line EGFR-TKI in Elderly Patients with NSCLC Harboring Sensitive EGFR Mutations (ID 11126)
12:00 - 13:30 | Author(s): Kenya Kanazawa
- Abstract
Background
Subsequent therapies confound the ability to discern the effect of first‑line chemotherapy on overall survival (OS). Therefore, the objective of our study was to determine the relationships between progression-free survival (PFS) or post-progression survival (PPS) and OS after first-line EGFR-TKI treatment in , using individual level data.
a9ded1e5ce5d75814730bb4caaf49419 Method
Between April 2008 and December 2015, we analyzed 68 cases of elderly patients with NSCLC harboring sensitive EGFR mutations treated with first-line EGFR-TKI. The relationships between PFS and PPS with OS were analyzed at an individual level.
4c3880bb027f159e801041b1021e88e8 Result
PPS was more closely associated with OS (R2 = 0.54) compared to PFS (R2 = 0.48), based on linear regression. Best response at first-line treatment, PS at the end of first-line treatment and administration of EGFR-TKI rechallenge were significantly linked to the PPS.
8eea62084ca7e541d918e823422bd82e Conclusion
PPS has a stronger impact on OS than PFS in elderly patients with NSCLC harboring sensitive EGFR mutations treated with first-line EGFR-TKI. fluenced by treatments subsequent to first-line chemotherapy; however, this remains to be verified with prospective studies.
6f8b794f3246b0c1e1780bb4d4d5dc53 -
+
P3.01-43 - Predictive Value of Computed Tomography Characteristics for Nivolumab Response in Pretreated Non-Small Cell Lung Cancer (ID 13054)
12:00 - 13:30 | Author(s): Kenya Kanazawa
- Abstract
Background
The efficacy and safety of nivolumab for the treatment of pretreated non-small cell lung cancer (NSCLC) have been established. We conducted a retrospective multicenter trial to determine the significance of computed tomography (CT) morphologic characteristics as a predictor of nivolumab efficacy for advanced NSCLC patients.
a9ded1e5ce5d75814730bb4caaf49419 Method
From April 2013 to March 2017, 78 pretreated NSCLC patients were enrolled. Our radiologist assessed the following tumor characteristics on CT before nivolumab treatment; interstitial septal thickening, peritumoral ground-glass opacity, spiculated margin, air bronchogram, cavity or necrosis, adjacent organ invasion, bulky lymph node (≥ 2.5 cm), and accumulation of small lymph nodes. After nivolumab treatment, objective response rate (ORR), disease control rate (DCR) and progression free survival (PFS) were analyzed with logistic regression and Cox proportional hazards regression models. Patient and CT morphologic characteristics were retrospectively analyzed. Significant parameters identified by univariate analysis were included in a multiple analysis.
4c3880bb027f159e801041b1021e88e8 Result
Of the 78 patients, 60 (77%) were male, and 72 (92%) patients were of performance status 0 to 1. Heavy smoking was related to higher ORR than light or never smoking (28% vs 0%, p=0.01)．No morphologic characteristics were related to ORR or DCR. Interstitial septal thickening was significantly associated with shorter PFS (p=0.015, 77 vs 126 days). Adjacent organ invasion was also significantly associated with shorter PFS (p=0.047, 72 vs 118 days). However, they were not found to be significant on multivariate analysis.
8eea62084ca7e541d918e823422bd82e Conclusion
Interstitial septal thickening and adjacent organ invasion may be negative prognostic factors of nivolumab treatment for NSCLC.
6f8b794f3246b0c1e1780bb4d4d5dc53
